Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

02. Oktober 2017 13:39 ET | Quelle: NuCana plc

NuCana plc Announces Closing of Initial Public Offering of ADSs and Exercise of Underwriters’ Option to Purchase Additional ADSs

EDINBURGH, United Kingdom, Oct. 02, 2017 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer...
27. September 2017 21:36 ET | Quelle: NuCana BioMed Limited

NuCana plc Announces Pricing of Initial Public Offering

EDINBURGH, United Kingdom, Sept. 27, 2017 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer...
13. September 2017 07:00 ET | Quelle: NuCana BioMed Limited

NuCana Announces Interim Data from First-In-Human Study of Transformative Anti-Cancer Agent, NUC-3373

EDINBURGH, United Kingdom, Sept. 13, 2017 (GLOBE NEWSWIRE) -- NuCana plc announced the presentation of interim first-in-human data from a Phase 1 clinical study of NUC-3373, its ProTide...
12. September 2017 07:00 ET | Quelle: NuCana BioMed Limited

NuCana Announces Positive Results of NUC-1031 (Acelarin®) in Advanced Ovarian Cancer at ESMO 2017

EDINBURGH, United Kingdom, Sept. 12, 2017 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company developing a portfolio of novel anti-cancer medicines called ProTides®, announced...